<DOC>
	<DOCNO>NCT01215123</DOCNO>
	<brief_summary>This observational study ass median time treatment duration safety Avastin ( bevacizumab ) first line treatment patient metastatic breast cancer . Data collect approximately 24 month .</brief_summary>
	<brief_title>An Observational Study Avastin ( Bevacizumab ) Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Patients metastatic breast cancer first line treatment complete treatment Avastin Patients willing unable sign write consent form</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>